Explaining biosimilars and how reverse engineering plays a critical role in their development
Author:
Affiliation:
1. Department of Rheumatology and NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK
Funder
not funded
Publisher
Informa UK Limited
Subject
Drug Discovery
Link
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2020.1796627
Reference51 articles.
1. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics
2. Biologics: structural heterogeneity and immunogenicity
3. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues
4. Bio – Biotechnology Innovation Organization. [cited Mar 2020]. Available from: https://archive.bio.org/articles/how-do-drugs-and-biologics-differ
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Methodological and regulatory aspects of pharmaceutical development of biological products;Pharmacy & Pharmacology;2024-01-29
2. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region;Expert Opinion on Biological Therapy;2023-07-26
3. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes;Analytical and Bioanalytical Chemistry;2023-05-10
4. Reverse Engineering of Medicinal and Nutritional Products - Approaches Available for Generic Product Development;Current Analytical Chemistry;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3